Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Colorectal Cancer | Research article

Knock-down of LRP/LR influences signalling pathways in late-stage colorectal carcinoma cells

Authors: Leila Vania, Gavin Morris, Eloise Ferreira, Stefan F. T. Weiss

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

The 37 kDa/67 kDa laminin receptor (LRP/LR) is involved in several tumourigenic-promoting processes including cellular viability maintenance and apoptotic evasion. Thus, the aim of this study was to assess the molecular mechanism of LRP/LR on apoptotic pathways in late stage (DLD-1) colorectal cancer cells upon siRNA-mediated down-regulation of LRP/LR.

Methods

siRNAs were used to down-regulate the expression of LRP/LR in DLD-1 cells which was assessed using western blotting and qPCR. To evaluate the mechanistic role of LRP/LR, proteomic analysis of pathways involved in proliferation and apoptosis were investigated. The data from the study was analysed using a one-way ANOVA, followed by a two-tailed student’s t-test with a confidence interval of 95%.

Results

Here we show that knock-down of LRP/LR led to significant changes in the proteome of DLD-1 cells, exposing new roles of the protein. Moreover, analysis showed that LRP/LR may alter components of the MAPK, p53-apoptotic and autophagic signalling pathways to aid colorectal cancer cells in continuous growth and survival. Knock-down of LRP/LR also resulted in significant decreases in telomerase activity and telomerase-related proteins in the DLD-1 cells.

Conclusions

These findings show that LRP/LR is critically implicated in apoptosis and cell viability maintenance and suggest that siRNA-mediated knock-down of LRP/LR may be a possible therapeutic strategy for the treatment of colorectal cancer.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

DiGiacomo V, Meruelo D. Looking into laminin receptor: critical discussion regarding the non-integrin 37/67-kDa laminin receptor/RPSA protein. Biol Rev. 2016;91(2):288–310. https://doi.org/10.1111/brv.12170.CrossRefPubMed

O’Donohue M-F, Choesmel V, Faubladier M, Fichant G, Gleizes P-E. Functional dichotomy of ribosomal proteins during the synthesis of mammalian 40S ribosomal subunits. J Cell Biol. 2010;190(5):853–66. https://doi.org/10.1083/jcb.201005117.CrossRefPubMedPubMedCentral

Kinoshita K, Kaneda Y, Sato M, Saeki Y, Wataya-Kaneda M, Hoffmann A, et al. LBP-p40 binds DNA tightly through associations with histones H2A, H2B, and H4. Biochem Biophys Res Commun. 1998;253(2):277–82. https://doi.org/10.1006/bbrc.1998.9699.CrossRefPubMed

Venticinque L, Meruelo D. Comprehensive proteomic analysis of nonintegrin laminin receptor interacting proteins. J Proteome Res. 2012;11(10):4863–72. https://doi.org/10.1021/pr300307h.CrossRefPubMedPubMedCentral

Venticinque L, Jamieson KV, Meruelo D. Interactions between laminin receptor and the cytoskeleton during translation and cell motility. PLoS One. 2011;6(1):e15895. https://doi.org/10.1371/journal.pone.0015895.CrossRefPubMedPubMedCentral

Thepparit C, Smith DR. Serotype-specific entry of dengue virus into liver cells: identification of the 37-kilodalton/67-kilodalton high-affinity laminin receptor as a dengue virus serotype 1 receptor. J Virol. 2004;78(22):12647–56. https://doi.org/10.1128/JVI.78.22.12647-12656.2004.CrossRefPubMedPubMedCentral

Gauczynski S, Peyrin JM, Haïk S, Leucht C, Hundt C, Rieger R, et al. The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. EMBO J. 2001;20(21):5863–75. https://doi.org/10.1093/emboj/20.21.5863.CrossRefPubMedPubMedCentral

Dias BDC, Jovanovic K, Gonsalves D, Moodley K, Reusch U, Knackmuss S, Weinberg MS, Little M, Weiss SF: The 37kDa/67kDa laminin receptor acts as a receptor for Aβ 42 internalization. 2014, 4:5556.

10.

Otgaar TC, Ferreira E, Malindisa S, Bernert M, Letsolo BT, Weiss SF. 37 kDa LRP:: FLAG enhances telomerase activity and reduces senescent markers in vitro. Oncotarget. 2017;8(49):86646–56. https://doi.org/10.18632/oncotarget.21278.CrossRefPubMedPubMedCentral

11.

Vania L, Chetty CJ, Ferreira E, Weiss SF. anti-LRP/LR–specific antibody igG1-iS18 significantly impedes adhesion and invasion in early-and late-stage colorectal carcinoma cells. Mol Med. 2016;22(1):664–73. https://doi.org/10.2119/molmed.2016.00169.CrossRefPubMedPubMedCentral

12.

Rebelo TM, Chetty CJ, Ferreira E, Weiss SF. Anti-LRP/LR-specific antibody IgG1-iS18 impedes adhesion and invasion of pancreatic cancer and neuroblastoma cells. BMC Cancer. 2016;16(1):917. https://doi.org/10.1186/s12885-016-2953-2.CrossRefPubMedPubMedCentral

13.

Vania L, Morris G, Otgaar TC, Bignoux MJ, Bernert M, Burns J, et al. Patented therapeutic approaches targeting LRP/LR for cancer treatment. 2019;29(12):987–1009.

14.

Omar A, Reusch U, Knackmuss S, Little M, Weiss SF. Anti-LRP/LR-specific antibody IgG1-iS18 significantly reduces adhesion and invasion of metastatic lung, cervix, colon and prostate cancer cells. J Mol Biol. 2012;419(1):102–9. https://doi.org/10.1016/j.jmb.2012.02.035.CrossRefPubMed

15.

Khusal R, Dias BDC, Moodley K, Penny C, Reusch U, Knackmuss S, et al. In vitro inhibition of angiogenesis by antibodies directed against the 37kDa/67kDa laminin receptor. PLoS One. 2013;8(3):e58888. https://doi.org/10.1371/journal.pone.0058888.CrossRefPubMedPubMedCentral

16.

Rebelo TM, Vania L, Ferreira E, Weiss SF. siRNA-mediated LRP/LR knock-down reduces cellular viability of malignant melanoma cells through the activation of apoptotic caspases. Exp Cell Res. 2018;368(1):1–12. https://doi.org/10.1016/j.yexcr.2018.04.003.CrossRefPubMed

17.

Chetty CJ, Ferreira E, Jovanovic K, Weiss SF. Knockdown of LRP/LR induces apoptosis in pancreatic cancer and neuroblastoma cells through activation of caspases. Exp Cell Res. 2017;360(2):264–72. https://doi.org/10.1016/j.yexcr.2017.09.016.CrossRefPubMed

18.

Vania L, Rebelo TM, Ferreira E, Weiss SFT. Knock-down of LRP/LR promotes apoptosis in early and late stage colorectal carcinoma cells via caspase activation. BMC Cancer. 2018;18(1):602. https://doi.org/10.1186/s12885-018-4531-2.CrossRefPubMedPubMedCentral

19.

Naidoo K, Malindisa ST, Otgaar TC, Bernert M, Dias BDC, Ferreira E, et al. Knock-down of the 37kDa/67kDa laminin receptor LRP/LR impedes telomerase activity. PLoS One. 2015;10(11):e0141618. https://doi.org/10.1371/journal.pone.0141618.CrossRefPubMedPubMedCentral

20.

Blackburn EH. Structure and function of telomeres. Nature. 1991;350(6319):569–73. https://doi.org/10.1038/350569a0.CrossRefPubMed

21.

Shay JW, Wright WE. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis. 2004;26(5):867–74.CrossRef

22.

Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science. 1997;277(5328):955–9. https://doi.org/10.1126/science.277.5328.955.CrossRefPubMed

23.

Choi J, Southworth LK, Sarin KY, Venteicher AS, Ma W, Chang W, et al. TERT promotes epithelial proliferation through transcriptional control of a Myc-and Wnt-related developmental program. PLoS Genet. 2008;4(1):e10. https://doi.org/10.1371/journal.pgen.0040010.CrossRefPubMedPubMedCentral

24.

Lee J, Sung Y, Cheong C, Choi Y, Jeon H, Sun W, et al. TERT promotes cellular and organismal survival independently of telomerase activity. Oncogene. 2008;27(26):3754–60. https://doi.org/10.1038/sj.onc.1211037.CrossRefPubMed

25.

Smogorzewska A, van Steensel B, Bianchi A, Oelmann S, Schaefer MR, Schnapp G, et al. Control of human telomere length by TRF1 and TRF2. Mol Cell Biol. 2000;20(5):1659–68. https://doi.org/10.1128/MCB.20.5.1659-1668.2000.CrossRefPubMedPubMedCentral

26.

Jovanovic K, Chetty CJ, Khumalo T, Da Costa DB, Ferreira E, Malindisa ST, et al. Novel patented therapeutic approaches targeting the 37/67 kDa laminin receptor for treatment of cancer and Alzheimer’s disease. Expert Opin Therapeutic Patents. 2015;25(5):567–82. https://doi.org/10.1517/13543776.2015.1014802.CrossRef

27.

Sundquist T, Moravec R, Niles A, O’Brien M, Riss T. Timing your apoptosis assays. Cell Notes. 2006;16:18–21.

28.

Yuan X, Xu D. Telomerase reverse transcriptase (TERT) in action: cross-talking with epigenetics. Int J Mol Sci. 2019;20(13):3338. https://doi.org/10.3390/ijms20133338.CrossRefPubMedCentral

29.

Smogorzewska A, de Lange T. Regulation of telomerase by telomeric proteins. Annu Rev Biochem. 2004;73(1):177–208. https://doi.org/10.1146/annurev.biochem.73.071403.160049.CrossRefPubMed

30.

Sun L, Liu L, Liu X, Wang Y, Li M, Yao L, et al. MGr1-Ag/37LRP induces cell adhesion-mediated drug resistance through FAK/PI3K and MAPK pathway in gastric cancer. Cancer Sci. 2014;105(6):651–9. https://doi.org/10.1111/cas.12414.CrossRefPubMedPubMedCentral

31.

Ludwig C, Gillet L, Rosenberger G, Amon S, Collins BC, Aebersold R. Data-independent acquisition-based SWATH-MS for quantitative proteomics: a tutorial. Mol Syst Biol. 2018:14(8).

32.

Wright WE, Shay JW. The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol. 1992;27(4):383–9. https://doi.org/10.1016/0531-5565(92)90069-C.CrossRefPubMed

33.

Poggesi M, Gelmini S, Raggi CC, Cianchi F, Valanzano R, Pazzagli M, Orlando C: The Significance of Quantitative Evaluation of Telomerase Activity and hTERT mRNA Expression in Colorectal Cancers. In: Madame Curie Bioscience Database [Internet]. edn.: Landes Bioscience; 2013.

34.

Yoshida R, Kiyozuka Y, Ichiyoshi H, Senzaki H, Takada H, Hioki K, et al. Change in telomerase activity during human colorectal carcinogenesis. Anticancer Res. 1999;19(3B):2167–72.PubMed

35.

Modugno M, Tagliabue E, Ardini E, Berno V, Galmozzi E, De Bortoli M, et al. p53-dependent downregulation of metastasis-associated laminin receptor. Oncogene. 2002;21(49):7478–87. https://doi.org/10.1038/sj.onc.1205957.CrossRefPubMed

36.

Rahman R, Latonen L, Wiman KG. hTERT antagonizes p53-induced apoptosis independently of telomerase activity. Oncogene. 2005;24(8):1320–7. https://doi.org/10.1038/sj.onc.1208232.CrossRefPubMed

37.

Xu D, Wang Q, Gruber A, Björkholm M, Chen Z, Zaid A, et al. Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene. 2000;19(45):5123–33. https://doi.org/10.1038/sj.onc.1203890.CrossRefPubMed

38.

Maida Y, Kyo S, Kanaya T, Wang Z, Yatabe N, Tanaka M, et al. Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. Oncogene. 2002;21(26):4071–9. https://doi.org/10.1038/sj.onc.1205509.CrossRefPubMed

39.

Nelson J, McFerran NV, Pivato G, Chambers E, Doherty C, Steele D, et al. The 67 kDa laminin receptor: structure, function and role in disease. Biosci Rep. 2008;28(1):33–48. https://doi.org/10.1042/BSR20070004.CrossRefPubMed

40.

Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279–90. https://doi.org/10.1038/sj.onc.1210421.CrossRefPubMed

41.

Yoon H, Dehart JP, Murphy JM, Lim S-TSJJoH, Cytochemistry: Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights 2015, 63(2):114–128.

42.

Wen AY, Sakamoto KM, LSJTJoI M. The role of the transcription factor CREB in immune function. 2010;185(11):6413–9.

43.

Craig A, Scott M, Burch L, Smith G, Ball K, TJEr H. Allosteric effects mediate CHK2 phosphorylation of the p53 transactivation domain. 2003;4(8):787–92.

44.

Choi CH, Chung J-Y, Cho H, Kitano H, Chang E, Ylaya K, et al. Prognostic significance of AMP-dependent kinase alpha expression in cervical cancer. 2015;82(5):203–11.

45.

Marino G, Niso-Santano M, Baehrecke EH, GJNrMcb K. Self-consumption: the interplay of autophagy and apoptosis. 2014;15(2):81.

46.

Schuler M, Bossy-Wetzel E, Goldstein JC, Fitzgerald P, DRJJoBC G. p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. 2000;275(10):7337–42.

47.

Vania L, Rebelo TM, Ferreira E, Weiss SF. Knock-down of LRP/LR promotes apoptosis in early and late stage colorectal carcinoma cells via caspase activation. BMC Cancer. 2018;18(1):602. https://doi.org/10.1186/s12885-018-4531-2.CrossRefPubMedPubMedCentral

48.

Olive PLJA. Endogenous DNA breaks: γH2AX and the role of telomeres. 2009;1(2):154.

49.

Maciejowski J, TJNrMcb DL. Telomeres in cancer: tumour suppression and genome instability. 2017;18(3):175.

Title: Knock-down of LRP/LR influences signalling pathways in late-stage colorectal carcinoma cells
Authors: Leila Vania
Gavin Morris
Eloise Ferreira
Stefan F. T. Weiss
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Colorectal Cancer
Colorectal Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08081-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Prospective pharmacological methodology for establishing and evaluating anti-cancer drug resistant cell lines

Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma

The value of complete blood count for the prognosis analysis of preoperative esophageal squamous cell carcinoma

Nomograms to predict the prognosis in locally advanced oral squamous cell carcinoma after curative resection

Machine learning-based Radiomics analysis for differentiation degree and lymphatic node metastasis of extrahepatic cholangiocarcinoma

Optimizing oropharyngeal cancer management by using proton beam therapy: trends of cost-effectiveness

Keynote webinar | Spotlight on antibody–drug conjugates in cancer